On the occasion of "National Hair Care Day" on August 18, the world's leading medical and health enterprises, together with the China Association of Non-public Medical Institutions and JD Health, jointly released the "Insight Report on The Investigation and Insight of Male Baldness in China" (hereinafter referred to as the "Report"), which not only focuses on the current situation of androgenic alopecia in the mainland, but also transmits professional treatment suggestions based on the clinical experience of clinicians and pharmacy experts, and discusses the development prospects of Internet + medical treatment in the field of hair treatment in combination with big data.
Guests jointly released the "Insight Report on The Investigation and Insight of Male Baldness in China"
Youth "thin hair", young people face the problem of early baldness
As one of the health problems that seriously affect the appearance of the face, the topic of "hair loss" has aroused a lot of social attention and discussion. According to the 2019 Chinese androgenic alopecia guidelines, androgenic alopecia ("androgenic alopecia") is the most common of many types of hair loss [1]. The prevalence of male andropsy is about 21.3% [2], meaning that one in five males develops androgeny. The number of people with male degeneration is increasingly large and showing a younger trend, and the demand for hair health is increasing day by day.
Today, with the vigorous development of the Internet, the increasingly active Internet information channels, including online medical platforms, online consultation platforms, and knowledge popularization platforms, provide diversified ways for the majority of patients to understand androgenism. However, uneven disease content often brings misunderstandings to patients and hinders correct disease cognition and treatment.
Misunderstandings are frequent, and hair loss is not simple
The report points out that the male population is not highly aware of their own diseases, and there are many misconceptions. For example, it is believed that all hair loss is not a disease, and it is better to wait for self-healing; It is believed that the main cause of hair loss is "big oil head", as long as the oil is controlled, it can stop the loss and so on; Or frequently try various trails of popular "hair growth recipes". In this regard, professor and chief physician of Huashan Hospital affiliated to Fudan University; The first president and honorary president of the Dermatologist Branch of the Chinese Medical Doctor Association; Zheng Zhizhong, chairman of the Skin Professional Committee of the China Association of Non-public Medical Institutions, said: "With the release of this report, we hope to call on the public to care for their own hair health. Anatomy is a disease that will be progressively aggravated, and if it is not taken seriously, it will become more and more serious, and even have a negative impact on the mental health of patients. Therefore, it is necessary to seek medical treatment as soon as possible, choose a regular hospital, carry out scientific and correct medicine according to the examination results, and maintain a good attitude and adhere to long-term and standardized treatment. ”
Lin Yuwei, Vice President of Marketing Department of Ogallon China Classic Brand, said: "Androgenic alopecia is a chronic disease that plagues the majority of men, and it is also one of the disease areas that Ogallon has been deeply cultivating for a long time. We hope that through this research report, on the one hand, we will help improve the public's awareness of anandogenism, so as to help patients cope with diseases scientifically; On the other hand, it also hopes to help the industry better understand trends, discover pain points, and innovate more targeted in the future to create value for patients. ”
"Top priority" is taken seriously, and the anti-shedding posture is unlocked scientifically
Based on in-depth interviews with authoritative clinical experts and pharmaceutical experts in the field of hair treatment in many parts of the country, the report "debunks" and gives professional advice on common androgenic cognitive misunderstandings, helping men with male problems with anddrosities to unlock the "correct posture" of scientific response to hair loss.
Professor Wu Wenyu, vice president of the Dermatology Professional Committee of the China Association of Non-public Medical Institutions, chairman of the Hair Medicine and Scalp Health Management Subcommittee, and deputy director of the Department of Dermatology of Huashan Hospital affiliated to Fudan University, put forward three suggestions: "First, the guidelines recommend that oral plus external combination drugs have a better effect. Second, the protection of hair needs to pay attention to the health of the hair follicle, and receive treatment in a regular hospital as soon as possible before the hair follicle is permanently closed. Third, if you choose hair transplantation, you also need to seek the help of medical professionals before and after hair transplantation and adhere to medication, so as to enhance and consolidate the results of surgery. ”
New Internet scene, hair preservation and baldness "saving males"
In recent years, the Internet has gradually become a "new scene" for hair loss diagnosis and treatment, and the sales of online prescription drugs have continued to grow, reflecting the fact that patients embrace the concept of scientific treatment, but also put forward more diversified demand for diagnosis and treatment channels. As a generation that grew up with the Internet, the post-80s and post-90s generations are more inclined to pursue more convenient, privacy-oriented and personalized medical and pharmaceutical services online. Therefore, Ogalon actively responds to the needs of patients, explores innovative practices that can meet the needs of medication in new scenarios on the Internet, and is committed to breaking through the barriers between online consultation and disease self-management, helping patients manage diseases scientifically and for a long time.
Shen Bin, Vice President of the Retail Division of Ogallon China Classic Brand, said: "We hope to work with partners such as digital medical platforms, Internet hospitals, hair transplant centers and other partners to build an industry ecosystem in the field of amphotism, and are committed to realizing a closed loop of full-cycle medical services from medicine to medicine, from diagnosis to solution, to better help patients manage diseases and help doctors improve diagnosis and treatment efficiency." ”
Wang Yiting, General Manager of JD Health Pharmaceutical Division, said: "JD Health and Ogalon have been working together for a long time in the field of hair health and other diseases, and we look forward to leveraging our digital advantages to jointly develop more valuable innovative services with partners to provide patients with one-stop health solutions and improve patients' experience in medication and disease management." ”
In 2022, Ogalon and JD Health jointly built an online "Hair Care Center" to synchronize the latest drug treatment plans and provide professional online pharmaceutical services for patients with male detachment. With the help of digital technology, the "Hair Care Center" will also launch many convenient service tools in the future, such as hair management self-test tools, etc., to help patients realize "staying at home" to understand their hair status, so as to achieve early detection and early diagnosis and treatment of diseases.
08-2024-CN-NON-110218
If you would like more information about your disease, please consult a healthcare professional
About Ogalon
Ogallon is a global healthcare company focused on protecting women's health throughout their life cycle. Ogalon offers a global portfolio of more than 60 pharmaceuticals and medical solutions covering a range of key disease treatment areas. With a leading women's health business, a growing biosimilar business, and a stable classic brand business, Ogalon is able to continue to invest in innovation and future growth opportunities in women's health with strong cash flow advantages. In addition, Ogallon is actively exploring partnerships with biopharmaceutical innovators to leverage the company's scale and resources in fast-growing international markets to help them commercialize and globalize their products.
Ogalon has achieved large-scale, wide-coverage development and world-class commercial operation capabilities around the world, headquartered in Jersey City, New Jersey, USA, and has approximately 9,000 employees worldwide.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements made in accordance with the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, management's expected statements about the Company's future financial performance and prospects. Forward-looking statements may be identified by words such as "hope," "anticipation," "potential," "intend," "foresee," "plan," "believe," "seek," "estimate," "will" or similar meanings. Such statements are based on the current perceptions and expectations of the Company's management, and important risks and uncertainties will have an impact on them. If the underlying assumptions prove to be in error, or risks or uncertainties arise, actual results may deviate materially from the results contained in any forward-looking statement.
Risks and uncertainties include, but are not limited to, the inability to execute on our business development strategy, or the inability to generate revenue from planned acquisitions; The overall environment and competition of the industry; General economic factors such as fluctuations in interest rates and currency exchange rates; the impact of the global COVID-19 pandemic; The impact of pharmaceutical industry regulation and healthcare legislation in the U.S. and international markets; Global trends in healthcare cost control; Scientific and technological progress, new products and patents obtained by competitors; Regulatory approval challenges arising from new product development; the company's ability to correctly predict future market conditions; Production impediments or delays; Financial instability due to international economic and political risks; Difficulties in developing and maintaining relationships with commercial counterparties; Reliance on the validity of the term of protection of the Company's patents and other innovative products; and the litigation involved, including patent litigation and/or regulatory measures.
The Company undertakes no obligation to publicly update any forward-looking statements as a result of new information, future events or otherwise. The Company's submissions to the U.S. Securities and Exchange Commission (SEC) set out other factors that could cause actual results to deviate significantly from those described in the forward-looking statements, including the Listing Registration Form on Form 10 and subsequent periodic reports, which can be found on the SEC's official website www.sec.gov.
Resources:
Hu Zhiqi,Miao Yong. guidelines for the diagnosis and treatment of Chinese androgenic alopecia[J].Chinese Journal of Aesthetic Plastic Surgery,2019,30(01):8-12.
[2] Wang Tinglin, Shen Youwei, Zhou Cheng, Wang Xiaoyan, Ding Xiaolan, Tian Shan, Liu Ying, Peng Guanghui, Xue Shuqi, Zhou Jun'e, Wang Renli, Meng Xuemei, Pei Guangde, Bai Yunhua, Liu Qing, Li Hang, Chen Jie, Cai Lin, Zhang Jianzhong. Epidemiological investigation of androgenic alopecia in six provinces of mainland China[J].Journal of Clinical Dermatology,2010,39(12):743-746.